ArticleThe journal of extra-corporeal technology2025
Evaluating the need for magnesium administration following cardioplegic arrest with del Nido cardioplegia solution.
Article in The journal of extra-corporeal technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modified Del Nido Cardioplegia with a 1:4 Crystalloid-to-Blood Ratio Versus Blood-Based St. Thomas Cardioplegia in Isolated Aortic Valve Replacement.Journal of cardiovascular development and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgrounddel Nido cardioplegia (dNC) solution is widely used in pediatric and congenital cardiac surgery. In 2014, Cincinnati Children's Hospital Medical Center (CCHMC) changed from Mee cardioplegic solution to dNC. Since Mee solution does not contain magnesium, magnesium was administrated post cross-clamp removal, at a dose of 25 mg/kg up to 1 g, to abate hypomagnesemia. This practice remained in place with the use of dNC. We postulated that patients may experience hypermagnesemia under this protocol.
methodsTo determine if exogenous magnesium is necessary post-clamp removal in our practice, a study examining serum magnesium levels during cardiopulmonary bypass (CPB) was completed from January 2022 through October 2023 (IRB #2021-0816). One hundred patients undergoing CPB with cross-clamp, ranging from infants to adults, were consented. Two magnesium samples were collected. Draw 1 (D1) was collected post cardioplegia administration and 30 min prior to cross-clamp removal. Draw 2 (D2) was collected post-cross-clamp removal and 10 ± 2 min following magnesium administration.
resultsBoth samples demonstrated magnesium levels > 1.6 mg/dL or higher (normal magnesium range at CCHMC, 1.6-2.6 mg/dL). A Wilcoxon rank sum test demonstrated statistical significance for D1, comparing the number of samples that fell above 2.6 mg/dL vs. those that fell within the normal range (p < 0.001). D2 demonstrated values above the normal range for all but one sample, which does not satisfy the criteria of the Wilcoxon rank sum test for demonstrating significance (p = 0.089); however, ninety-nine samples displayed hypermagnesemia.
conclusionThis study demonstrates that exogenous magnesium administration may not be necessary in the setting of our practice at CCHMC and dNC cardioplegic arrest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.